Vaxart, Inc.
NASDAQ:VXRTBiotechnology
-$0.01 today
- Market cap
- $129.30M
- Beta
- 1.09
- P/E (TTM)
- 3.6
- EPS (TTM)
- $0.15
Volume 0.12M
Average 0.41M
VXRT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Vaxart, Inc.NASDAQ: VXRT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $5.18M, compared with -$15.59M a year earlier. Trailing-twelve-month net income was $37.1M.
Context
- Net income amounted to 6.9% of revenue in FY2025, down 226.4 pp from a year earlier.
- Net income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$87.53M (-636.1%) for the fiscal year ending Dec 2026, a slowdown from the +124.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5.18M-90.6% QoQ
- Last fiscal yearDec 2025
- $16.33M+124.4% YoY
- LTMMar 2026
- $37.1M+163.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +133.2% | +239.4% | +106.2 pp |
| 1 year | +124.4% | -636.1% | -760.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 16.33M USD
- Year-over-year change
- +124.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.33M | +124.4% |
| FY2024 | 2024-12-31 | (66.95M) | +18.8% |
| FY2023 | 2023-12-31 | (82.47M) | +23.5% |
| FY2022 | 2022-12-31 | (107.76M) | -52.9% |
| FY2021 | 2021-12-31 | (70.47M) | — |
Net Income vs competitors
How VXRT compares with its peers on the latest reported figures
- VXRT's LTM Mar 2026 net income of $37.1M is the smallest of the 10 companies compared; the peer median is $78.34M.
- Its year-over-year change of +163.8% is the 2nd highest of 10, against a peer median of +8.2%.
- Net income amounts to 14.5% of revenue for VXRT, versus a peer median of 1777.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.31M | -5.5% | +25.1% | 1360.6% | |
| LTM Mar 2026 | $104.29M | +8.2% | -6.9% | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $103.27M | -65.4% | +96.0% | 2409.4% |
| LTM Mar 2026 | $102.15M | +215.2% | -46.4% | 154.4% | |
| LTM Mar 2026 | $86.3M | +66.7% | — | 2193.7% | |
| LTM Mar 2026 | $78.34M | +28.7% | +2.0% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $77.27M | -7.7% | +35.7% | — |
| LTM Mar 2026 | $58.88M | -22.2% | -28.5% | — | |
| LTM Mar 2026 | $39.95M | +162.9% | +13.7% | — | |
| LTM Mar 2026 | $37.1M | +163.8% | — | 14.5% | |
| Peer median (excluding VXRT) | $78.34M | +8.2% | +7.8% | 1777.2% | |
Competitors are the stored peer set for VXRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (70.47M) | (107.76M) | (82.47M) | (66.95M) | 16.33M |
| Depreciation & Amortization | 4.21M | 5.81M | 8.62M | 8.85M | 8.58M |
| Deferred Income Tax | 3.09M | 4.09M | 0 | 0 | 0 |
| Stock-Based Compensation | 8.87M | 13.59M | 14.13M | 11.5M | 8.31M |
| Change in Working Capital | (2.12M) | (4.7M) | (10.85M) | 3.26M | (22.56M) |
| Accounts Receivables | 263K | 51K | (2.99M) | (2.75M) | (39.38M) |
| Inventory | 0 | (7.11M) | 0 | 0 | 0 |
| Accounts Payables | 1.63M | 357K | (2.44M) | 5.27M | 14.64M |
| Other Working Capital | (4.01M) | 2M | (5.42M) | 742K | 2.17M |
| Other Non-Cash Items | (3.41M) | (5.81M) | 106K | (1.43M) | (2.94M) |
| Operating Cash Flow | (59.83M) | (94.78M) | (70.45M) | (44.76M) | 7.71M |
| Capital Expenditures | (5.16M) | (9.6M) | (1.87M) | (554K) | (145K) |
| Acquisitions (Net) | (4.83M) | 10.81M | 120K | 0 | 0 |
| Purchases of Investments | (44.81M) | (55.01M) | (27.5M) | (54.33M) | (19.03M) |
| Sales of Investments | 5.7M | 44.2M | 73.2M | 43.5M | 40M |
| Other Investing Activities | 0 | (10.81M) | 0 | (9.95M) | (4.2M) |
| Investing Cash Flow | (49.1M) | (20.42M) | 43.95M | (21.32M) | 16.63M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 122.21M | 17.24M | 15.03M | 56.78M | 4.44M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.59M | 225K | 213K | (214K) | (199K) |
| Financing Cash Flow | 125.8M | 17.46M | 15.24M | 56.56M | 4.24M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 16.88M | (97.73M) | (11.26M) | (9.53M) | 28.59M |
| Free Cash Flow | (64.99M) | (104.38M) | (72.32M) | (45.32M) | 7.57M |
Vaxart, Inc.
NASDAQ:VXRT
Intrinsic Alpha fair value
Locked
Current Price
$0.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.